BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32126143)

  • 1. Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.
    Shrestha R; Sakata-Yanagimoto M; Maie K; Oshima M; Ishihara M; Suehara Y; Fukumoto K; Nakajima-Takagi Y; Matsui H; Kato T; Muto H; Sakamoto T; Kusakabe M; Nannya Y; Makishima H; Ueno H; Saiki R; Ogawa S; Chiba K; Shiraishi Y; Miyano S; Mouly E; Bernard OA; Inaba T; Koseki H; Iwama A; Chiba S
    Blood Adv; 2020 Mar; 4(5):845-854. PubMed ID: 32126143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and prognosis analysis of
    Zhang T; Zhao Y; Zhao Y; Zhou J
    Aging (Albany NY); 2020 Mar; 12(6):5031-5047. PubMed ID: 32209730
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
    Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
    Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
    Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
    J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.
    Ko M; Bandukwala HS; An J; Lamperti ED; Thompson EC; Hastie R; Tsangaratou A; Rajewsky K; Koralov SB; Rao A
    Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14566-71. PubMed ID: 21873190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
    Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
    Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
    [No Abstract]   [Full Text] [Related]  

  • 10. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.
    Quivoron C; Couronné L; Della Valle V; Lopez CK; Plo I; Wagner-Ballon O; Do Cruzeiro M; Delhommeau F; Arnulf B; Stern MH; Godley L; Opolon P; Tilly H; Solary E; Duffourd Y; Dessen P; Merle-Beral H; Nguyen-Khac F; Fontenay M; Vainchenker W; Bastard C; Mercher T; Bernard OA
    Cancer Cell; 2011 Jul; 20(1):25-38. PubMed ID: 21723201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes.
    Laukka T; Mariani CJ; Ihantola T; Cao JZ; Hokkanen J; Kaelin WG; Godley LA; Koivunen P
    J Biol Chem; 2016 Feb; 291(8):4256-65. PubMed ID: 26703470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TET2 missense variants in human neoplasia. A proposal of structural and functional classification.
    Bussaglia E; Antón R; Nomdedéu JF; Fuentes-Prior P
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00772. PubMed ID: 31187595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.
    Cai Z; Kotzin JJ; Ramdas B; Chen S; Nelanuthala S; Palam LR; Pandey R; Mali RS; Liu Y; Kelley MR; Sandusky G; Mohseni M; Williams A; Henao-Mejia J; Kapur R
    Cell Stem Cell; 2018 Dec; 23(6):833-849.e5. PubMed ID: 30526882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
    Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
    Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
    Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
    Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlapping Requirements for Tet2 and Tet3 in Normal Development and Hematopoietic Stem Cell Emergence.
    Li C; Lan Y; Schwartz-Orbach L; Korol E; Tahiliani M; Evans T; Goll MG
    Cell Rep; 2015 Aug; 12(7):1133-43. PubMed ID: 26257178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.
    Pethusamy K; Seethy A; Dhar R; Karmakar A; Chaudhary S; Bakhshi S; Palanichamy JK; Chopra A; Chauhan SS; Karmakar S
    Leuk Lymphoma; 2022 Dec; 63(14):3426-3432. PubMed ID: 36165590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
    Corces-Zimmerman MR; Hong WJ; Weissman IL; Medeiros BC; Majeti R
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2548-53. PubMed ID: 24550281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.